Distinct effects of rosuvastatin and rosuvastatin/ezetimibe on senescence markers of CD8+ T cells in patients with type 2 diabetes mellitus: a randomized controlled trial
ConclusionsWe observed a reduction in senescent CD8+ T cells and an increase in the ratio of naive to memory CD8+ T cells with rosuvastatin/ezetimibe treatment. Our results demonstrate the immunomodulatory roles of ezetimibe in combination with statins, independent of improvements in lipid or HbA1c levels.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
More News: Cholesterol | Crestor | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Rosuvastatin | Statin Therapy | Vytorin | Zetia